AffiliationDepartment of Endocrinology, Manchester Royal Infirmary &Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractPituitary tumours are benign but cause significant problems, both because of their compressive effects on brain structures and also because of the syndromes of hormone excess or deficiency that they can cause. Endocrine therapy has become increasingly successful, with the development of dopamine agonists and somatostatin analogues. Recently growth hormone receptor antagonists have been developed by modification of the GH molecule. It is likely that further advances based on our understanding of the biology will dramatically improve the treatment of these tumours.
CitationPituitary tumour therapy: using the biology. 2002, 14 (12):1p following 978 J. Neuroendocrinol.
JournalJournal of Neuroendocrinology
- The role of somatostatin analogues in the treatment of neuroendocrine tumours.
- Authors: Grozinsky-Glasberg S, Grossman AB, Korbonits M
- Issue date: 2008 May 14
- Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
- Authors: Plöckinger U, Quabbe HJ
- Issue date: 2005 May
- The treatment algorithm of acromegaly.
- Authors: Colao A, Pivonello R, Cappabianca P, Vitale G, Lombardi G
- Issue date: 2003
- Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
- Authors: Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD
- Issue date: 2007 Aug
- The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology.
- Authors: Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, Esposito D, Minuto F
- Issue date: 2009 May